Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 2
2007 1
2008 1
2009 1
2013 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Circulation. 2004 Jul 27;110(4):386-91. doi: 10.1161/01.CIR.0000136588.62638.5E. Epub 2004 Jul 19. Circulation. 2004. PMID: 15262833 Clinical Trial.
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Schwartz GG, et al. JAMA. 2001 Apr 4;285(13):1711-8. doi: 10.1001/jama.285.13.1711. JAMA. 2001. PMID: 11277825 Clinical Trial.
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):142-7. doi: 10.1161/ATVBAHA.107.151787. Epub 2007 Nov 8. Arterioscler Thromb Vasc Biol. 2008. PMID: 17991875 Clinical Trial.
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Atherosclerosis. 2009 Oct;206(2):551-5. doi: 10.1016/j.atherosclerosis.2009.03.020. Epub 2009 Mar 26. Atherosclerosis. 2009. PMID: 19394618 Clinical Trial.
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Tsimikas S, et al. Circulation. 2004 Sep 14;110(11):1406-12. doi: 10.1161/01.CIR.0000141728.23033.B5. Epub 2004 Sep 7. Circulation. 2004. PMID: 15353498 Clinical Trial.